Microarray Expression Profiling and Raman Spectroscopy Reveal Anti-Fatty Liver Action of Berberine in a Diet-Induced Larval Zebrafish Model

Background: The prevalence of non-alcohol fatty liver disease (NAFLD) is increasing in children and adolescents who are mostly resulted from overfeeding. Previous studies demonstrate that berberine (BBR), a compound derived from plant, has beneficial effects on NAFLD in adults but poorly understood in the pediatric population. This study employed a larval zebrafish model to mimic the therapeutic effects of BBR in the pediatric population and the mechanisms underlying its hepatoprotection. Methods: High-cholesterol diet (HCD)-fed zebrafish exposed to BBR at doses of 0, 1, 5, and 25 μM. After the larvae were treated with BBR for 10 days, its effect on hepatic steatosis was evaluated. We introduced Raman imaging and three-dimensional (3D) molecular imaging to detect changes in the biochemical composition and reactive oxygen species (ROS) levels of zebrafish liver. Gene expression microarray was performed to identify differentially expressed genes (DEGs) followed by gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, and functional category analysis. Results: BBR (5 and 25 μM) administration prevented HCD-induced liver lipid accumulation in larval zebrafish. The result was further confirmed by the pathological observation. Raman mapping indicated that the biochemical composition in the liver of BBR-treated group shifted to the control. The quantitative analysis of 3D imaging showed that the ROS level was significantly decreased in the liver of BBR-treated larvae. In the livers of the BBR group, we found 468 DEGs, including 172 genes with upregulated expression and 296 genes with downregulated expression. Besides, GO enrichment, KEGG pathway, and functional category analysis showed that various processes related to glucolipid metabolism, immune response, DNA damage and repair, and iron were significantly enriched with DEGs. The expression levels of the crucial genes from the functional analysis were also confirmed by quantitative PCR (qPCR). Conclusion: BBR can significantly improve hepatic steatosis in HCD-fed zebrafish larvae. Its mechanisms might be associated with the regulation of lipid metabolism, oxidative stress, and iron homeostasis. Raman imaging in larval zebrafish might become a useful tool for drug evaluation. Mainly, the gene expression profiles provide molecular information for BBR on the prevention and treatment of pediatric NAFLD.

[1]  Runping Liu,et al.  Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes , 2020, PloS one.

[2]  Haowen Jiang,et al.  Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans , 2019, Cell Death & Disease.

[3]  H. Hosseinzadeh,et al.  Berberine and barberry (Berberis vulgaris): A clinical review , 2019, Phytotherapy research : PTR.

[4]  Runsen Chen,et al.  Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway , 2019, Current Medical Science.

[5]  Runsen Chen,et al.  Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2/ARE signalling pathway , 2019, Experimental and therapeutic medicine.

[6]  S. Zang,et al.  Berberine prevents non-alcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice. , 2019, American journal of translational research.

[7]  Jian-Dong Jiang,et al.  Syntaxin 1B Mediates Berberine’s Roles in Epilepsy-Like Behavior in a Pentylenetetrazole-Induced Seizure Zebrafish Model , 2018, Front. Mol. Neurosci..

[8]  Tingting Hu,et al.  Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  J. Friedman,et al.  Mitochondrial role in the neonatal predisposition to developing nonalcoholic fatty liver disease , 2018, The Journal of clinical investigation.

[10]  V. Nobili,et al.  Unmet needs in pediatric NAFLD research: what do we need to prioritize for the future? , 2018, Expert review of gastroenterology & hepatology.

[11]  Bo Chen,et al.  Comparative Study of Different Diets-Induced NAFLD Models of Zebrafish , 2018, Front. Endocrinol..

[12]  Changqin Hu,et al.  Cardiac safety evaluation in zebrafish and in silico ADME prediction of cephalosporins with an aminothiazoyl ring at the C‐7 position , 2018, Toxicology and applied pharmacology.

[13]  Yiming Yu,et al.  shinyCircos: an R/Shiny application for interactive creation of Circos plot , 2018, Bioinform..

[14]  Xin Gao,et al.  Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21 , 2018, British journal of pharmacology.

[15]  Hongyang Wang,et al.  Microbiota transplantation reveals beneficial impact of berberine on hepatotoxicity by improving gut homeostasis , 2017, Science China Life Sciences.

[16]  M. Jenmalm The mother–offspring dyad: microbial transmission, immune interactions and allergy development , 2017, Journal of internal medicine.

[17]  V. Alla,et al.  Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. , 2017, Diabetes & metabolic syndrome.

[18]  Filippo Del Bene,et al.  CRISPR/Cas9-Mediated Knockin and Knockout in Zebrafish , 2017 .

[19]  Jingfeng Liu,et al.  Circulating tumor DNA profiling reveals clonal evolution and real‐time disease progression in advanced hepatocellular carcinoma , 2017, International journal of cancer.

[20]  Y. Liu,et al.  Embryo and Developmental Toxicity of Cefazolin Sodium Impurities in Zebrafish , 2017, Front. Pharmacol..

[21]  C. Alves,et al.  Nonalcoholic fatty liver disease (NAFLD) pathophysiology in obese children and adolescents: update , 2017, Nutricion hospitalaria.

[22]  P. So,et al.  Development of a classification model for non‐alcoholic steatohepatitis (NASH) using confocal Raman micro‐spectroscopy , 2017, Journal of Biophotonics.

[23]  E. Levy,et al.  Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. , 2017, Antioxidants & redox signaling.

[24]  Yingli Lu,et al.  Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease , 2017, BMC Endocrine Disorders.

[25]  M. Raponi,et al.  Clinical implications of understanding the association between oxidative stress and pediatric NAFLD , 2017, Expert review of gastroenterology & hepatology.

[26]  Chung S. Yang,et al.  Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway , 2017, Molecular Pharmacology.

[27]  J. Adjaye,et al.  Concise Review: Current Status and Future Directions on Research Related to Nonalcoholic Fatty Liver Disease , 2016, Stem cells.

[28]  Clinical Implications. , 2017, Hypertension.

[29]  B. Neuschwander‐Tetri,et al.  In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. , 2016, Gastroenterology.

[30]  Xin Gao,et al.  The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease , 2016, Molecules.

[31]  A. Feldstein,et al.  Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. , 2016, Metabolism: clinical and experimental.

[32]  Sjoerd Stallinga,et al.  Deconvolution methods for structured illumination microscopy. , 2016, Journal of the Optical Society of America. A, Optics, image science, and vision.

[33]  T. Kietzmann,et al.  Reactive oxygen species and fibrosis: further evidence of a significant liaison , 2016, Cell and Tissue Research.

[34]  E. Elinav,et al.  Non-alcoholic fatty liver and the gut microbiota , 2016, Molecular metabolism.

[35]  A. Alisi,et al.  Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. , 2016, Gastroenterology.

[36]  Zheng-Xiao Zhao,et al.  Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. , 2016, Biochemical and biophysical research communications.

[37]  R. A. Forse,et al.  Pediatric Nonalcoholic Fatty Liver Disease: the Rise of a Lethal Disease Among Mexican American Hispanic Children , 2016, Obesity Surgery.

[38]  Yinshi Sun,et al.  Preparative Isolation of Two Prenylated Biflavonoids from the Roots and Rhizomes of Sinopodophyllum emodi by Sephadex LH-20 Column and High-Speed Counter-Current Chromatography , 2015, Molecules.

[39]  Yiyue Zhang,et al.  High fat plus high cholesterol diet lead to hepatic steatosis in zebrafish larvae: a novel model for screening anti-hepatic steatosis drugs , 2015, Nutrition & Metabolism.

[40]  Haishan Zeng,et al.  Accurate assessment of liver steatosis in animal models using a high throughput Raman fiber optic probe. , 2015, The Analyst.

[41]  W. Jia,et al.  Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease , 2015, PloS one.

[42]  D. Weghuber,et al.  The Potential Role of Iron and Copper in Pediatric Obesity and Nonalcoholic Fatty Liver Disease , 2015, BioMed research international.

[43]  Mary E Rinella,et al.  Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.

[44]  Jinrong Peng,et al.  Genetic ablation of solute carrier family 7a3a leads to hepatic steatosis in zebrafish during fasting , 2014, Hepatology.

[45]  R. Matthews,et al.  Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition , 2014, Hepatology.

[46]  G. Paradies,et al.  Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. , 2014, World journal of gastroenterology.

[47]  K. Kochan,et al.  Raman imaging providing insights into chemical composition of lipid droplets of different size and origin: in hepatocytes and endothelium. , 2014, Analytical chemistry.

[48]  Nicolas C Pégard,et al.  Three-dimensional deconvolution microfluidic microscopy using a tilted channel , 2013, Journal of biomedical optics.

[49]  Miriam B. Vos,et al.  Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. , 2013, The Journal of pediatrics.

[50]  M. Rämet,et al.  The zebrafish as a model for paediatric diseases , 2013, Acta paediatrica.

[51]  Amnon Schlegel Studying non-alcoholic fatty liver disease with zebrafish: a confluence of optics, genetics, and physiology , 2012, Cellular and Molecular Life Sciences.

[52]  F. Marlow,et al.  Mutations in vacuolar H+ -ATPase subunits lead to biliary developmental defects in zebrafish. , 2012, Developmental biology.

[53]  Qing-You Zhang,et al.  Expression pattern and functions of autophagy-related gene atg5 in zebrafish organogenesis , 2011, Autophagy.

[54]  S. Kalhan,et al.  Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis , 2011, European journal of gastroenterology & hepatology.

[55]  E. Feskens,et al.  Sharply higher rates of iron deficiency in obese Mexican women and children are predicted by obesity-related inflammation rather than by differences in dietary iron intake. , 2011, The American journal of clinical nutrition.

[56]  D. Swinkels,et al.  Effect of body mass index reduction on serum hepcidin levels and iron status in obese children , 2010, International Journal of Obesity.

[57]  E. Ikonen,et al.  Zebrafish: gaining popularity in lipid research. , 2010, The Biochemical journal.

[58]  Soo-Ho Choi,et al.  Vascular Lipid Accumulation, Lipoprotein Oxidation, and Macrophage Lipid Uptake in Hypercholesterolemic Zebrafish , 2009, Circulation research.

[59]  Matthew B Veldman,et al.  Zebrafish as a Developmental Model Organism for Pediatric Research , 2008, Pediatric Research.

[60]  A. Roach,et al.  Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery , 2008, British journal of pharmacology.

[61]  I. Mavromichalis,et al.  Update on non-alcoholic fatty liver disease in children. , 2007, Clinical nutrition.

[62]  K. Widhalm,et al.  The association between non‐alcoholic fatty liver disease and insulin resistance in 20 obese children and adolescents , 2007, Acta paediatrica.

[63]  C. Sirlin,et al.  Pediatric Nonalcoholic Fatty Liver Disease: A Critical Appraisal of Current Data and Implications for Future Research , 2006, Journal of pediatric gastroenterology and nutrition.

[64]  乾 あやの,et al.  小児期の nonalcoholic fatty liver disease (NAFLD) , 2006 .

[65]  P. Ciampalini,et al.  NAFLD in children: A prospective clinical‐pathological study and effect of lifestyle advice , 2006, Hepatology.

[66]  H. Barr,et al.  Raman spectroscopy: elucidation of biochemical changes in carcinogenesis of oesophagus , 2006, British Journal of Cancer.

[67]  C. Day From fat to inflammation. , 2006, Gastroenterology.

[68]  G. Li Volti,et al.  Antioxidant treatment inhibited glutamate-evoked NF-kappaB activation in primary astroglial cell cultures. , 2005, Neurotoxicology.

[69]  J. Halterman,et al.  Overweight children and adolescents: a risk group for iron deficiency. , 2004, Pediatrics.

[70]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[71]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[72]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[73]  M. George Unmet needs. , 1991, Nursing times.